2021年9月至2022年9月在一项多中心前瞻性队列研究中5至11岁儿童对新型冠状病毒肺炎信使核糖核酸疫苗的体液免疫反应

Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022.

作者信息

Lyski Zoe L, Porter Cynthia, Uhrlaub Jennifer L, Ellingson Katherine D, Jeddy Zuha, Gwynn Lisa, Rivers Patrick, Sprissler Ryan, Hegmann Kurt T, Coughlin Melissa, Fowlkes Ashley, Hollister James, LeClair Lindsay, Mak Josephine, Beitel Shawn C, Fuller Sammantha, Grant Lauren, Newes-Adeyi Gabriella, Yoo Young M, Olsho Lauren, Burgess Jefferey L, Caban-Martinez Alberto, Yoon Sarang, Britton Amadea, Gaglani Manjusha, Lutrick Karen

机构信息

Immunobiology, College of Medicine-Tucson, University of Arizona, University of Arizona Health Sciences, Tucson, Arizona, USA.

Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.

出版信息

Open Forum Infect Dis. 2023 Aug 12;10(8):ofad431. doi: 10.1093/ofid/ofad431. eCollection 2023 Aug.

DOI:10.1093/ofid/ofad431

PMID:37663086

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10468733/

Abstract

BACKGROUND

The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections.

METHODS

Children aged 5-11 years had serum collected 14-59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2).

RESULTS

79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 ( = .009) and Omicron ( = .02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease ( < .001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval, .29-.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06-1.57]).

CONCLUSIONS

Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection.

摘要

背景

PROTECT研究是一项纵向队列研究，于2021年7月启动，在亚利桑那州、佛罗里达州、得克萨斯州和犹他州这4个州对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进行每周检测。本研究旨在检查疫苗引发的针对接种疫苗后SARS-CoV-2感染的抗体反应。

方法

5至11岁儿童在接种第二剂单价辉瑞-BioNTech 2019冠状病毒病信使核糖核酸疫苗后14至59天采集血清。使用曲线下面积（AUC）和终点滴度，通过酶联免疫吸附测定法（受体结合域[RBD]和S2）以及针对原始毒株（WA1）和奥密克戎毒株（BA.2）的替代中和试验来测量疫苗引发的抗体。

结果

79名接种疫苗的参与者（33名[41.7%]为女性；中位年龄8.8岁[标准差1.9岁]），48名（60.8%）来自亚利桑那州图森市；64名（81.0%）为非西班牙裔白人；63名（80.8%）亲自上学；68名（86.1%）没有任何慢性病；47名（59.5%）在接种疫苗后感染。未感染儿童针对WA1（P = 0.009）和奥密克戎（P = 0.02）的AUC更高。检测限以上的几何平均替代中和滴度，针对WA1为346.0，针对奥密克戎为39.7，下降了8.7倍（P < 0.001）。在WA1特异性模型中调整协变量后，我们观察到RBD AUC每增加一个标准差，接种疫苗后感染的几率降低47%（调整后比值比，0.53[95%置信区间，0.29 - 0.97]），RBD终点滴度每增加3倍，感染几率降低69%（0.31[0.06 - 1.57]）。